Cell and Gene Therapy

Solving the challenges of targeted and tuned expression through synthetic promoters and enabling the next generation of gene therapies.

Sarah Haecker Meeks

Sarah Haecker Meeks, PhD
Vice President, Business Development

  • Optimize your expression cassette with variable size promoters
  • Increase in vivo targeting with our tissue selective promoters and improve safety by reducing off target expression
  • Increase expression by incorporating stronger, more potent promoters
  • Choose constitutive or inducible promoters specific to your therapeutic product mechanism of action

Synpromics’ novel approach to synthetic promoter development means that it is now possible to develop new promoters to improve cell and gene therapy products. To meet our partners’ needs, we can either select and outlicense candidates from existing promoter libraries or alternatively engage in a design and development program to deliver promoters with particular criteria that are unique to a partner’s specific application.